LIN — Linde plc

The market is split: analysts remain constructive (consensus Buy, 25 Buy/3 Hold, average target around $563), and Q2 2026 showed +9.4% YoY revenue growth and a record $8.1B backlog. But as of 2026-09-13 the stock was down 10.95% over 3 months, 5.61% over 6 months, and below all key moving averages, reflecting multiple-compression worries from elevated rates, Lincare healthcare headwinds, rising capex, and Middle East-driven materials-sector risk-off. That produces a neutral, not bullish, read despite good operating results.

Revenue has steadily grown from roughly $8.1B-$8.3B per quarter in 2023-2024 to $9.289B in Q2 2026, with YoY growth accelerating from +2.8% in Q2 2025 and +3.1% in Q3 2025 to +8.3% in Q1 2026 and +9.4% in Q2 2026. Diluted EPS rose from $3.73 in Q2 2025 to $4.15 in Q2 2026, though Q4 2025 was soft ($3.26 EPS, $2.018B operating income). Operating margin was 27.3% in Q2 2026 vs 27.7% in Q2 2025, a slight compression, and Q2 2026 FCF fell to $833M from $954M a year earlier as capex rose to $1.438B from $1.257B. The trend is modestly accelerating on revenue/EPS but not yet margin-expanding; record backlog and 18% electronics growth suggest the acceleration may be more structural than a one-quarter blip, while capex intensity is the offset.

As of 2026-09-13, LIN traded at $466.22, or 29.96x TTM EPS of $15.755 and 26.1x next-FY estimated EPS of $17.88. That is below its 5-year average P/E of 35.61x, so versus its own history it is not expensive; the deterministic valuation context labels it Neutral vs. its own history. But PEG is 2.94, P/B is 5.52x, EV/EBITDA is about 17.8x, and trailing FCF yield is only around 2.3%, so it is not outright cheap. I would call the stock fairly valued: quality and backlog justify a premium, but elevated rates and moderate low-teens EPS growth cap multiple expansion.

The key mismatch as of 2026-09-13 is that price has fallen 10.95% over three months while Q2 2026 revenue grew 9.4% YoY and adjusted EPS rose 10% to $4.50. The market is not disputing near-term earnings; it is compressing the multiple on rate, capex, and healthcare concerns. At 26x forward EPS, LIN needs only modest re-rating to 28x-30x to justify $500-$536; consensus at about $563 implies roughly 31.5x forward. If Q3 2026 confirms backlog conversion and FY26 EPS guidance of $17.70-$17.90, the current price likely underprices steady execution. If capex keeps rising and Lincare volumes weaken, the multiple can stay stuck.

As of 2026-09-13, RSI was 34.47, close to oversold but not below 30; price was 3.02% below its 20-day SMA, 6.21% below its 50-day SMA, and 3.18% below its 200-day SMA. Returns were -2.38% over 1 week, -2.76% over 1 month, -10.95% over 3 months, and -5.61% over 6 months. The chart is in a short-to-intermediate downtrend, not merely range-bound. Oversold bounces are possible, but a trend reversal would need a reclaim of the 50-day and 200-day averages; entry-timing favors waiting for stabilization or scaling in only for longer-horizon investors.

• Elevated Treasury yields and interest rates are pressuring high-quality compounder multiples, including LIN's roughly 30x trailing P/E.
• Energy/natural-gas and power input costs matter for industrial gas production, though Linde's contracts mostly pass through cost inflation with a lag.
• Middle East escalation and crude near $100/barrel triggered materials-sector risk-off and broader macro uncertainty in the weeks before 2026-09-13.
• Secular semiconductor/advanced-node fab demand and clean-energy/decarbonization projects are structural tailwinds, reinforced by Linde's record $8.1B sale-of-gas backlog and 18% electronics growth in Q2 2026.
• U.S. home healthcare reimbursement and volume pressure at Lincare is a company-specific macro/regulatory drag on the healthcare segment.

• Q3 2026 earnings release, expected late October/early November 2026: backlog conversion, capex pacing, and any update to FY26 adjusted EPS guidance of $17.70-$17.90.
• Conversion of the record $8.1B sale-of-gas backlog, including roughly $1B of new electronics contracts for Western U.S. advanced-node fabs, into revenue and earnings.
• Strategic updates on Lincare/healthcare, which could clarify whether that segment remains a drag or becomes a fixable/divestable asset.
• Interest-rate path and any Treasury-yield relief that could support multiple re-rating for defensive quality compounders.
• Continued semiconductor, commercial space, and clean-energy project awards that add to backlog and reinforce the secular growth narrative.

• Sustained elevated interest rates could keep compressing LIN's P/E even if earnings grow, limiting share-price upside.
• Rising capex, including $1.438B in Q2 2026 alone, could pressure free cash flow; Q2 2026 FCF fell to $833M from $954M a year earlier.
• Lincare healthcare reimbursement and U.S. home healthcare volume headwinds could cap multiple expansion and offset industrial gas growth.
• Current ratio of 0.879 and quick ratio of 0.747 are below 1.0, leaving less near-term balance-sheet liquidity cushion if macro conditions tighten.
• Industrial end-market softening or energy-cost volatility could slow revenue/EPS growth, especially if backlog conversion slips.

Linde is a wide-moat, high-quality industrial gas compounder with stable take-or-pay contracts, record backlog, and accelerating 2026 revenue/EPS growth, but the stock is not a screaming bargain at roughly 26x forward EPS and is technically weak. The deterministic score correctly calls it Fair Fundamentals/Neutral, and the risk/reward is balanced: Q3 execution and rate relief could drive upside toward my roughly $501 fair value and consensus around $563, but multiple compression, capex, and Lincare headwinds argue against chasing. I would treat this as a watchlist/accumulate-on-weakness name rather than a high-conviction buy at the 2026-09-13 price.

I apply a 28x forward P/E to next-FY estimated EPS of $17.88, yielding $500.64. The 28x multiple is my reasoned fair multiple: a discount to the 5-year average P/E of 35.61x due to higher rates, but a premium to the current forward multiple of roughly 26.1x, justified by Linde's wide moat, low beta of 0.727, record $8.1B backlog, and expected low-teens EPS growth.